# Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL

> **NCT04548700** · PHASE1 · TERMINATED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 38 (actual)

## Conditions studied

- Treatment-naïve
- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
- **DRUG:** Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone

## Key facts

- **NCT ID:** NCT04548700
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-24
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** The sponsor has adjusted its R\&D strategy.
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04548700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04548700, "Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04548700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*